NGEN Stock Price, Chart, Stats & News
NervGen Pharma Corp. Common stock (NGEN) does not currently pay a dividend.
NGEN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -195.93% |
ROE | 239118.67% |
D/E | -0.01x |
Interest coverage ratio | – |
NGEN valuation
P/E | – |
P/S | – |
P/B | -126.78x |
P/CF | -22.47x |
P/FCF | -24.33x |
P/OCF | -22.47x |
PEG | -3.93x |
EV multiple | -16.24x |
About
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
Similar securities
Based on sector and market capitalization
